Floatz logo

Oricar-017

Neoplasms by Histologic Type

OriCell Therapeutics Co., Ltd.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

927 Active assets in the Neoplasms by Histologic Type cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Vinorelbine
Shi Yanxia
Phase 3BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Oricar-017 is also rated in:

plasma cell myelomaDormant
CC
Indicative ·
45 / 100
View asset →
Vascular DiseasesDormant
CC
Indicative ·
43 / 100
View asset →
vascular hemostatic diseaseDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →